Cancer Research Targets Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dai, W.
Right arrow Articles by Rao, C. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dai, W.
Right arrow Articles by Rao, C. V.
[Cancer Research 64, 440-445, January 15, 2004]
© 2004 American Association for Cancer Research

Advances in Brief

Slippage of Mitotic Arrest and Enhanced Tumor Development in Mice with BubR1 Haploinsufficiency

Wei Dai1, Qi Wang1, Tongyi Liu1, Malisetty Swamy4, Yuqiang Fang1, Suqing Xie1, Radma Mahmood2, Yang-Ming Yang1, Ming Xu3 and Chinthalapally V. Rao4

1 Division of Molecular Carcinogenesis, Department of Medicine, New York Medical College, Valhalla, New York;
2 Core Facility for Histopathology, Albert Einstein College of Medicine, Bronx, New York;
3 Department of Cell Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio; and
4 Institute for Cancer Prevention, Valhalla, New York


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
A compromised spindle checkpoint is thought to play a key role in genetic instability that predisposes cells to malignant transformation. Loss of function mutations of BubR1, an important component of the spindle checkpoint, have been detected in human cancers. Here we show that BubR1+/- mouse embryonic fibroblasts are defective in spindle checkpoint activation, contain a significantly reduced amount of securin and Cdc20, and exhibit a greater level of micronuclei than do wild-type cells. RNA interference-mediated down-regulation of BubR1 also greatly reduced securin level. Moreover, compared with wild-type littermates, BubR1+/- mice rapidly develop lung as well as intestinal adenocarcinomas in response to challenge with carcinogen. BubR1 is thus essential for spindle checkpoint activation and tumor suppression.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
The spindle checkpoint functions to block the anaphase entry until each of every condensed chromosome has successfully attached to the spindle microtubules. Vertebrate BubR1 plays a key role in spindle checkpoint activation, during which it is extensively phosphorylated (1) . Hyperphosphorylated BubR1 and other components of the checkpoint machinery, including Bub1, Bub3, Mad1, Mad2, and CENP-E, are associated with unattached kinetochores (2 , 3) . Although it appears that BubR1 and Mad2 may function in a single pathway after spindle checkpoint activation (4) , BubR1 is a much more potent inhibitor of the anaphase-promoting complex (APC) than is Mad2 (5) . A recent study shows that spindle checkpoint activation or silencing is mediated through CENP-E-dependent activation or inactivation of BubR1 kinase (6) . A loss of spindle checkpoint function is thought to contribute to the development of cancer because of its role in maintaining genomic stability (7) . Indeed, aneuploidy is prevalent in many types of cancer. Although the physiological and molecular basis of this abnormality remains unclear, recent studies indicate that chromosomal instability is closely associated with the loss of a functional spindle checkpoint (7) . Mutations in BubR1 have been detected in colonic cancers (8) . In addition, a recent study has shown that BubR1 is epigenetically down-regulated in a substantial fraction of human cancers (9) . To determine the physiological function of BubR1, we have generated BubR1 mutant mice. Mouse embryonic fibroblasts (MEFs) from BubR1+/- animals were found to contain lower levels of securin and Cdc20 as well as BubR1 than MEFs from wild-type embryos. BubR1 deficiency resulted in mitotic slippage and formation of micronuclei at an enhanced rate. Moreover, BubR1+/- animals were prone to rapid development of tumors in multiple organs after exposure to a carcinogen.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Immunoblot Analysis.
MEFs or HeLa cells were suspended in a lysis buffer (1) , and the cell lysates were centrifuged at 12,000 x g for 10 min at 4°C. Equal amounts of proteins were then subjected to SDS-PAGE and immunoblot analysis with antibodies to BubR1, securin (Novocastra), Mad2, Cdc20, Plk3, or {alpha}-tubulin (Sigma). Immune complexes were detected with an appropriate second antibody conjugated with horseradish peroxidase (Sigma) and enhanced chemiluminescence reagents (Amersham Pharmacia Biotech).

Fluorescence Microscopy and Immunohistochemistry.
Cells fixed in methanol were treated with 0.1% Triton X-100 on ice and then washed three times with ice-cold PBS. After blocking with 2.0% BSA in PBS for 15 min on ice, cells were incubated for 1 h with antibodies to BubR1, {alpha}-tubulin, or CREST; washed with PBS; and then incubated with appropriate second antibodies conjugated with Rodamine-Red-X or FITC (Jackson ImmunoResearch). Cells were finally stained with 4',6-diamidino-2-phenylindole (1 µg/ml; Fluka). Fluorescence microscopy was performed on a Nikon microscope, and images were captured using a digital camera (Optronics). Immunohistochemistry was performed using a kit purchased from Vector Laboratory according to the instructions provided by the supplier.

RNA Interference.
Double-stranded RNAs of 21 nucleotides in length were synthesized by Dharmacon Research. The targeting sequence was 5'-AAGGGAAGCCGAGCUGUUGAC-3', corresponding to the coding region of 1281–1301 in human BubR1 (accession number AF068760 GenBank) and 1259–1279 in mouse BubR1 (accession number NM009773 GenBank) relative to the first nucleotide of ATG start codon. The control small interfering RNA (siRNA) targets luciferase mRNA (accession number X65324) of the firefly (Photinus pyralis), and the targeting sequence was 5'-UUCCTACGCTGAGTACTTCGA-3' (GL-3; Dharmacon Research). Double nucleotides (dTdT) were added at the 3' end of each strand. RNA duplexes were transfected into HeLa cells via the Oligofectamine approach (Invitrogen).

Mouse Carcinogenesis Assay.
At 6 weeks of age, female mice (10 wild-type and 10 BubR1+/-) were fed semipurified AIN-76A diets. One week after initiation of diets, both groups of mice were given s.c. azoxymethane (AOM; 4 mg/kg body weight) two times weekly for 4 weeks. All animals were weighed once every 2 weeks until termination of the study. Eight or 12 weeks after carcinogen treatment, mice were sacrificed by CO2 euthanasia, and their colons were removed and flushed with Krebs Ringer solution. The dissected colons were opened and fixed flat between two pieces of filter paper in 10% buffered formalin for microadenoma analysis. After a minimum of 24 h in buffered formalin, the colons were cut into segments and placed in a Petri dish containing 0.2% methylene blue in Krebs Ringer solution. They were then placed mucosal side up on a microscope slide and observed through a light microscope. The colon microadenomas present were scored according to standard procedures that are being used routinely in our laboratory (10) . Colons showing adenoma-like masses were fixed and subjected to histological analysis after H&E staining.


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
To study the consequence of loss of BubR1 function on genetic instability and tumor formation, we have generated BubR1 mutant mice (11) . BubR1 deficiency results in early embryonic death (11) . To confirm that BubR1+/- cells actually contained a reduced level of BubR1, we examined the abundance of BubR1 in MEFs derived from embryonic day 14.5 embryos produced from intercrosses of BubR1+/- mice. The genotype of each MEF line was determined by nested PCR (11) . Immunoblot analysis revealed that the amount of BubR1 in BubR1+/- MEFs was less than that in wild-type MEFs (Fig. 1A)Citation . Interestingly, the average level of BubR1 in BubR1+/- MEFs was about 25% (rather than the expected 50%) of that in wild-type MEFs (data not shown). This greatly reduced level of BubR1 apparently failed to accumulate at kinetochores during early mitosis (Fig. 1B)Citation , suggesting that BubR1 in BubR1+/- MEFs may not be efficiently activated. Indeed, exposure to the spindle checkpoint activator nocodazole for 16 h resulted in an apparent upshift of BubR1 due to phosphorylation1 in wild-type MEFs but not in BubR1+/- MEFs (Fig. 1A)Citation . Thus, ablation of one BubR1 allele apparently reduced the expression of the other allele, and the reduced level of BubR1 also compromised its activation after microtubule disruption.



View larger version (40K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Compromised spindle checkpoint function in BubR1+/- mouse embryonic fibroblasts (MEFs). A, wild-type and BubR1+/- MEF cells were incubated in the absence or presence (with a duplicate) of nocodazole (Noc; 0.5 µg/ml) for 16 h, after which cell lysates were prepared and subjected to immunoblot analysis with antibodies to BubR1 or to {alpha}-tubulin. BubR1-P denotes phosphorylated BubR1. B, wild-type and BubR1+/- MEF cells were fixed and stained with the antibody to BubR1 (green), and DNA was stained with 4',6-diamidino-2-phenylindole (blue). A representative prophase cell from either cell type is shown. Bar, 2 µm. C, BubR1+/- and wild-type MEFs were incubated with nocodazole (0.5 µg/ml) for the indicated times, after which equal amounts of cell lysates were subjected to immunoblot analysis with antibodies to securin, BubR1, Mad2, Cdc20, or {alpha}-tubulin. Data in all panels are representative of at least three independent experiments. D, HeLa cells transfected with small interfering RNA (siRNA) for 3 or 5 days were assayed for BubR1, securin, or {alpha}-tubulin expression via immunoblotting.

 
BubR1 functions as a potent inhibitor of APC during activation of the spindle checkpoint (5) . Metaphase and anaphase transition requires the destruction of securin in an APC-dependent manner. Cells with a compromised spindle checkpoint would be expected to exhibit increased APC activity and a consequent reduced abundance of securin. Indeed, immunoblot analysis revealed that the amount of securin in cycling BubR1+/- MEFs was reduced compared with that in wild-type cells. Although nocodazole induced a slight accumulation of securin in BubR1+/- MEFs, the steady-state level of this protein was much lower in these cells than in wild-type MEFs treated with nocodazole for the same time (Fig. 1C)Citation , consistent with the notion that BubR1+/- cells are defective in spindle checkpoint control. In addition, the abundance of Cdc20 was low in cycling BubR1+/- MEFs. On nocodazole treatment, Cdc20 was greatly increased in these cells. The kinetics of Cdc20 increase in BubR1+/- MEFs was similar to that observed in wild-type MEFs until about 18 h posttreatment; Cdc20 in these cells then returned to a level lower than that in wild-type MEFs (Fig. 1CCitation , 18 h and beyond). Moreover, a significant fraction of BubR1 in wild-type MEFs, but not in BubR1+/- MEFs, was phosphorylated on nocodazole treatment, and the phosphorylation peaked between 14 and 18 h posttreatment. On the other hand, Mad2 levels in BubR1+/- MEFs were not significantly modulated in the presence or absence of nocodazole.

To confirm that BubR1 deficiency directly caused a reduction of securin, we examined securin levels in HeLa cells transfected with siRNAs targeting human BubR1 or luciferase (as a negative control). BubR1 siRNA, but not control one, effectively down-regulated BubR1 expression 3 days after transfection (Fig. 1D)Citation . Consistently, the securin level was also significantly reduced. By day 5, securin had almost completely disappeared from HeLa cells transfected with siRNA targeting BubR1.

To determine whether mitosis was affected in BubR1+/- MEFs, we examined the percentage of cells positive for phosphorylated histone H3, a mitotic marker tightly associated with chromosome condensation (Fig. 2A)Citation . Fluorescence microscopy revealed that there existed significantly fewer phosphorylated histone H3-positive cells in BubR1+/- MEFs than in wild-type MEFs (Fig. 2B)Citation . About 3.8% of BubR1+/- MEFs were in mitotic stages as revealed by phosphorylated histone H3 staining, whereas 9.2% of cells were mitotic in wild-type MEFs (Fig. 2C)Citation . Chromosome mis-segregation and micronuclei formation are hallmarks of a compromised spindle checkpoint (7) . A greatly increased number of BubR1+/- MEF cells contained spontaneously formed micronuclei compared with the wild-type MEFs (Fig. 2, D and E)Citation . Irregular nuclear shape and nuclear blebbing were also observed in BubR1+/- MEFs (data not shown).



View larger version (37K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Mitotic slippage associated with abnormal nuclear morphology in BubR1+/- deficient cells. A, wild-type mouse embryonic fibroblasts (MEFs) fixed and stained with antibodies to phosphorylated histone H3 (H3-P; green) or kinetochore antigen CREST (red) were examined by fluorescence microscopy. DNA was stained with 4',6-diamidino-2-phenylindole. A typical prophase cell strongly stained with phosphorylated histone H3 is shown. Bar, 10 µm. B, BubR1+/- and wild-type MEFs fixed and stained with an antibody to phosphorylated histone H3 (green, top panels) and 4',6-diamidino-2-phenylindole (blue, bottom panels). Bar, 50 µm. C, both BubR1+/- and wild-type MEFs positive for phosphorylated histone H3 were scored from 500 cells, and the percentage of the positive cells is shown. D, BubR1+/- and wild-type MEFs stained with antibody to {alpha}-tubulin and 4',6-diamidino-2-phenylindole were examined by fluorescence microscopy. Arrows denote micronuclei. Bar, 5 µm. E, micronuclei formed in both BubR1+/- and wild-type MEFs were scored from 500 cells; the percentage of cells with micronuclei is shown.

 
Because mutations of the BubR1 gene were first identified in human colon cancer cells (8) and because BubR1 is epigenetically down-regulated in a substantial fraction of human cancers (9) , we investigated whether BubR1+/- mice were more susceptible to carcinogenesis after treatment with AOM, a colon carcinogen. Wild-type mice typically develop a low incidence of colonic tumors 6–8 months after initiation of AOM treatment (12) . About 2 months after the completion of AOM treatment, BubR1+/- mice had already exhibited abnormal and dilated crypts (data not shown). These mice subsequently developed a significant number of microadenomas and adenoma-like masses (Fig. 3BCitation ; Table 1Citation ). Polyps were scarcely detected in colons of wild-type C57/BL6 mice at this stage of treatment (Table 1)Citation , however. Histological studies revealed that when compared with the normal structure of colon, these polyps were indeed neoplastic (Table 1Citation ; Fig. 3, C and DCitation ). Colonic tubular adenomas were lined with mild dysplastic epithelium, and glands exhibited partial loss of polarity with a mild architecture distortion (Fig. 3C)Citation . Based on common pathological criteria (e.g., gland architecture, nuclear/cytoplasmic ratio, nuclear location, and amount of interglandular stroma), many large tumors from BubR1+/- animals were classified as well to moderately differentiated adenocarcinomas with complex and highly packed glands (Fig. 3D)Citation .



View larger version (102K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. BubR1+/- mice are more susceptible to the development of intestinal tumors. Both BubR1+/- and wild-type mice were treated with azoxymethane (AOM) for 5 weeks as described in "Materials and Methods." A and B, 8 weeks after AOM treatment, colons from individual mice were collected and stained with methylene blue. A topographical view of a typical wild-type colon section is shown in A, and a similar colon section with abnormal masses from a BubR1+/- mouse is shown in B. Arrows indicate focal of adenoma-like masses observed only in BubR1+/- mice. All images were obtained with a x4 lens. Bar, 2 mm. C, H&E-stained colon sections from BubR1+/+ and BubR1+/- mice treated with AOM (magnification, x40). A colonic adenoma from BubR1+/- mice treated with AOM appears in the bottom panel. D, H&E-stained sections of various adenocarcinomas from BubR1+/- mice treated with AOM (magnification, x100).

 

View this table:
[in this window]
[in a new window]

  		Table 1 Effect of azoxymethane on tumor formation in wild-type and BubR1+/- mice

 
We next examined several other major organs (e.g., spleen, liver, and lung) for any sign of tumor formation. No neoplastic growths were detected in either BubR1+/- or wild-type spleens. To our surprise, BubR1+/- mice, but not the wild-type mice, developed many lung adenocarcinomas (Fig. 4A)Citation as well as neoplasm in liver (data not shown). Tumor masses were typically well circumscribed, but not encapsulated, and situated at the periphery of the lung. They exhibited hyperchromatic and pleomorphic nuclei with abundant eosinophilic cytoplasm. Consistent with pulmonary adenocarcinoma, some tumor cells apparently formed glands with a lumen, whereas others formed trabecular patterns (Fig. 4A)Citation . Immunohistochemical studies revealed that lung adenocarcinomas were strongly stained with proliferative cell nuclear antigen (Fig. 4B)Citation , indicating that these tumor cells were highly proliferative. The susceptibility of BubR1+/- mice to lung tumor formation after challenge with the colon carcinogen AOM is unexpected because C57/BL6 mice are very resistant to the development of tumors, even when the lung-specific carcinogens such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone are used. It is intriguing to note that lung appears prone to development of cancer when the spindle checkpoint is compromised because Mad2 or Bub3 haploinsufficiency also results in enhanced development of lung cancer (13 , 14) .



View larger version (74K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. BubR1+/- mice, but not wild-type mice, develop lung adenomas after exposure to azoxymethane. A, lung sections from BubR1+/+ and BubR1+/- mice treated with azoxymethane for 12 weeks were stained with H&E (magnifications, x100 and x400, respectively). Arrow indicates a solitary tumor mass in BubR1+/- lung; the region is subjected to high-power magnification. B, neighboring sections of the same lung tissue from BubR1+/- mice were subjected to immunohistochemical studies after staining with either control immunoglobulin (IgG) or proliferative cell nuclear antigen IgG (magnifications, x100). Arrows indicate a solitary tumor; the same region is subjected to high-power magnification (x400).

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
Extensive biochemical and molecular analyses have shown that BubR1 plays a central role in spindle checkpoint activation (5 , 15 , 16) . It both coordinates the interaction of Bub3, Mad1, Mad2, and CENP-E with kinetochores and contributes to inhibition of APC activity during activation of this checkpoint. The APC is an E3 ubiquitin ligase that mediates the polyubiquitination of securin, thereby targeting it for degradation by the proteosome (16) . Securin binds to and inhibits the proteolytic activity of separase, which destroys the link between sister chromatids by cleaving the chromatid cohesin factor Scc1. Degradation of securin is required for the separation of sister chromatids during mitosis. Reduced levels of securin in BubR1+/- MEFs are closely correlated with BubR1 deficiency as well as with its activation status (Fig. 1C)Citation . Moreover, down-regulation of BubR1 via RNA interference resulted in almost complete disappearance of securin (Fig. 1D)Citation , strongly suggesting that BubR1 plays a pivotal role in the inhibition of APC during spindle checkpoint activation. In fact, enhanced genetic instability (e.g., polyploidy and micronuclei formation) in BubR1+/- MEF cells correlates very well with the observation that securin-/- cells lose chromosomes with a high frequency (17) .

It is believed that one of the consequences of the loss of spindle checkpoint is genetic instability of the resulting daughter cells, which predisposes these cells to malignant transformation. Some evidence indicates that structural alterations or a loss of functional spindle checkpoint components may trigger certain cancers because mutations have been detected in Bub1 and BubR1 (8 , 18) . Although we have not observed a significant increase in spontaneous tumors in BubR1+/- mice, our recent studies have demonstrated that these mice are prone to the development of neoplastic lesions of colon and lung within 2 months after they have been challenged with the carcinogen. In contrast, neither lesion is detected in wild-type mice at the same treatment stage, suggesting that BubR1 is a tumor susceptibility gene. Consistently, recent in vitro studies show that adenomatous polyposis coli protein plays an important role in chromosomal segregation by interacting with BubR1 and that defects in adenomatous polyposis coli lead to increased chromosomal instability (19) , underscoring the importance of further exploration of the role of BubR1 in colon cancer using this animal model. Intriguingly, it is expected that a significantly compromised spindle checkpoint observed with BubR1+/- MEF cells would conceivably lead to widespread aneuploidy and rapid development of spontaneous tumors in the transgenic animals. Our explanations are as follows: (a) the spindle checkpoint in BubR1+/- cells is compromised, but not completely failed; and (b) animals are capable of elimination of most cells with severe chromosomal instabilities through apoptosis. This mechanism would prevent the early onset of tumors until a second insult occurs during aging or under a carcinogen stress. This view is supported by the facts that haploinsufficiency of Mad2 and Bub3/Rae1 results in a significantly enhanced lung cancer incidence in aging (beyond 18 months; Ref. 13 ) and carcinogen-challenged (20) mice, respectively.

In this study, we have addressed an in vivo role of BubR1 by using a mouse gene knockout approach. BubR1 haploinsufficiency results in a compromised spindle checkpoint, leading to slippage of mitotic arrest. A recent study shows that CENP-E functions as an activator of the essential checkpoint kinase BubR1; inactivation of BubR1 kinase activity silences the signaling of the spindle checkpoint (6) . Thus, the availability of BubR1+/- mice should now greatly facilitate characterization of the functional interactions between BubR1 and various spindle checkpoint components, including CENP-E, Mad2, and other spindle checkpoint gene products.


   ACKNOWLEDGMENTS
 
We thank Dr. Robert Benezra and Dr. Jasminder Weinstein for Mad2 and Cdc20 antibodies, respectively. We are also grateful to Drs. Rulong Shen and Chung-Xiong Wang for discussions and valuable input about mouse histology. We also thank Dr. C. Clifford Conaway for reading the manuscript.


   FOOTNOTES
 
Grant support: NIH Grants RO1-CA90658 (to W. D.) and RO1-CA80003 (to C. V. R.).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Wei Dai, Division of Molecular Carcinogenesis, Department of Medicine, New York Medical College, Valhalla, New York 10595.

1 Wei Dai and Tongyi Liu, unpublished data. Back

Received 10/ 3/03. Revised 11/15/03. Accepted 11/26/03.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Li W., Lan Z., Wu H., Wu S., Meadows J., Chen J., Zhu V., Dai W. BUBR1 phosphorylation is regulated during mitotic checkpoint activation. Cell Growth Differ., 10: 769-775, 1999.[Abstract/Free Full Text]
  2. Sudakin V., Chan G. K., Yen T. J. Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J. Cell Biol., 154: 925-936, 2001.[Abstract/Free Full Text]
  3. Chen R. H. BubR1 is essential for kinetochore localization of other spindle checkpoint proteins and its phosphorylation requires Mad1. J. Cell Biol., 158: 487-496, 2002.[Abstract/Free Full Text]
  4. Shannon K. B., Canman J. C., Salmon E. D. Mad2 and BubR1 function in a single checkpoint pathway that responds to a loss of tension. Mol. Biol. Cell, 13: 3706-3719, 2002.[Abstract/Free Full Text]
  5. Hoyt M. A. A new view of the spindle checkpoint. J. Cell Biol., 154: 909-911, 2001.[Abstract/Free Full Text]
  6. Mao Y., Abrieu A., Cleveland D. W. Activating and silencing the mitotic checkpoint through CENP-E-dependent activation/inactivation of BubR1. Cell, 114: 87-98, 2003.[CrossRef][Medline]
  7. Rajagopalan H., Nowak M. A., Vogelstein B., Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat. Rev. Cancer, 3: 695-701, 2003.[CrossRef][Medline]
  8. Cahill D. P., Lengauer C., Yu J., Riggins G. J., Willson J. K., Markowitz S. D., Kinzler K. W., Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature (Lond.), 392: 300-303, 1998.[CrossRef][Medline]
  9. Shichiri M., Yoshinaga K., Hisatomi H., Sugihara K., Hirata Y. Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res., 62: 13-17, 2002.[Abstract/Free Full Text]
  10. Rao C. V., Desai D., Simi B., Kulkarni N., Amin S., Reddy B. S. Inhibitory effect of caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation in rat colon. Cancer Res., 53: 4182-4188, 1993.[Abstract/Free Full Text]
  11. Wang, Q., Liu, T-Y., Fang, Y-Q., Xie, S-Q., Huang, X., Ramashiwamy, G., Sakamoto, K., Dayzynkiewicz, Z., Xu, M., and Dai, W. BUBR1 deficiency results in abnormal megakaryopoiesis. Blood, in press, 2004.
  12. Csuka O., Szentirmay Z., Sugar J. The effect of promoters on 1,2-dimethylhydrazine-induced colon carcinogenesis. IARC Sci. Publ., 56: 129-136, 1984.
  13. Michel L. S., Liberal V., Chatterjee A., Kirchwegger R., Pasche B., Gerald W., Dobles M., Sorger P. K., Murty V. V., Benezra R. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature (Lond.), 409: 355-359, 2001.[CrossRef][Medline]
  14. Babu J. R., Jeganathan K. B., Baker D. J., Wu X., Kang-Decker N., van Deursen J. M. Rae1 is an essential mitotic checkpoint regulator that cooperates with Bub3 to prevent chromosome missegregation. J. Cell Biol., 160: 341-353, 2003.[Abstract/Free Full Text]
  15. Chan G. K., Jablonski S. A., Sudakin V., Hittle J. C., Yen T. J. Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC. J. Cell Biol., 146: 941-954, 1999.[Abstract/Free Full Text]
  16. Musacchio A., Hardwick K. G. The spindle checkpoint: structural insights into dynamic signalling. Nat. Rev. Mol. Cell Biol., 3: 731-741, 2002.[CrossRef][Medline]
  17. Jallepalli P. V., Waizenegger I. C., Bunz F., Langer S., Speicher M. R., Peters J. M., Kinzler K. W., Vogelstein B., Lengauer C. Securin is required for chromosomal stability in human cells. Cell, 105: 445-457, 2001.[CrossRef][Medline]
  18. Reis R. M., Nakamura M., Masuoka J., Watanabe T., Colella S., Yonekawa Y., Kleihues P., Ohgaki H. Mutation analysis of hBUB1, hBUBR1 and hBUB3 genes in glioblastomas. Acta Neuropathol. (Berl.), 101: 297-304, 2001.[Medline]
  19. Kaplan K. B., Burds A. A., Swedlow J. R., Bekir S. S., Sorger P. K., Nathke I. S. A role for the adenomatous polyposis coli protein in chromosome segregation. Nat. Cell Biol., 3: 429-432, 2001.[CrossRef][Medline]
  20. Meyn M. S. Ataxia-telangiectasia and cellular responses to DNA damage. Cancer Res., 55: 5991-6001, 1995.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 JCBHome page
M. Li, X. Fang, Z. Wei, J. P. York, and P. Zhang
Loss of spindle assembly checkpoint-mediated inhibition of Cdc20 promotes tumorigenesis in mice
J. Cell Biol., June 15, 2009; 185(6): 983 - 994.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
I. Ganmore, G. Smooha, and S. Izraeli
Constitutional aneuploidy and cancer predisposition
Hum. Mol. Genet., April 15, 2009; 18(R1): R84 - R93.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Tomasini, K. Tsuchihara, C. Tsuda, S. K. Lau, M. Wilhelm, A. Ruffini, M.-s. Tsao, J. L. Iovanna, A. Jurisicova, G. Melino, et al.
TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity
PNAS, January 20, 2009; 106(3): 797 - 802.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H.-S. Kim, Y.-K. Jeon, G.-H. Ha, H.-Y. Park, Y.-J. Kim, H.-J. Shin, C. G. Lee, D.-H. Chung, and C.-W. Lee
Functional Interaction between BubR1 and Securin in an Anaphase-Promoting Complex/CyclosomeCdc20-Independent Manner
Cancer Res., January 1, 2009; 69(1): 27 - 36.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Schliekelman, D. O. Cowley, R. O'Quinn, T. G. Oliver, L. Lu, E.D. Salmon, and T. Van Dyke
Impaired Bub1 Function In vivo Compromises Tension-Dependent Checkpoint Function Leading to Aneuploidy and Tumorigenesis
Cancer Res., January 1, 2009; 69(1): 45 - 54.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. Diaz-Rodriguez, R. Sotillo, J.-M. Schvartzman, and R. Benezra
Hec1 overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivo
PNAS, October 28, 2008; 105(43): 16719 - 16724.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
D. Qiao, X. Yang, K. Meyer, and A. Friedl
Glypican-1 Regulates Anaphase Promoting Complex/Cyclosome Substrates and Cell Cycle Progression in Endothelial Cells
Mol. Biol. Cell, July 1, 2008; 19(7): 2789 - 2801.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Suehiro, T. Okada, T. Okada, K. Anno, N. Okayama, K. Ueno, M. Hiura, M. Nakamura, T. Kondo, A. Oga, et al.
Aneuploidy Predicts Outcome in Patients with Endometrial Carcinoma and Is Related to Lack of CDH13 Hypermethylation
Clin. Cancer Res., June 1, 2008; 14(11): 3354 - 3361.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Kim, J. Liao, M. L. Dowling, K. R. Voong, S. E. Parker, S. Wang, W. S. El-Deiry, and G. D. Kao
TRAIL Inactivates the Mitotic Checkpoint and Potentiates Death Induced by Microtubule-Targeting Agents in Human Cancer Cells
Cancer Res., May 1, 2008; 68(9): 3440 - 3449.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Ebi, K. Matsuo, N. Sugito, M. Suzuki, H. Osada, K. Tajima, R. Ueda, and T. Takahashi
Novel NBS1 Heterozygous Germ Line Mutation Causing MRE11-Binding Domain Loss Predisposes to Common Types of Cancer
Cancer Res., December 1, 2007; 67(23): 11158 - 11165.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G.-H. Ha, K.-H. Baek, H.-S. Kim, S.-J. Jeong, C.-M. Kim, F. McKeon, and C.-W. Lee
p53 Activation in Response to Mitotic Spindle Damage Requires Signaling via BubR1-Mediated Phosphorylation
Cancer Res., August 1, 2007; 67(15): 7155 - 7164.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
Y. Niikura, A. Dixit, R. Scott, G. Perkins, and K. Kitagawa
BUB1 mediation of caspase-independent mitotic death determines cell fate
J. Cell Biol., July 10, 2007; 178(2): 283 - 296.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Magnaghi-Jaulin, G. Eot-Houllier, G. Fulcrand, and C. Jaulin
Histone Deacetylase Inhibitors Induce Premature Sister Chromatid Separation and Override the Mitotic Spindle Assembly Checkpoint
Cancer Res., July 1, 2007; 67(13): 6360 - 6367.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
E. Myslinski, M.-A. Gerard, A. Krol, and P. Carbon
Transcription of the human cell cycle regulated BUB1B gene requires hStaf/ZNF143
Nucleic Acids Res., May 11, 2007; 35(10): 3453 - 3464.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
I. Perez de Castro, G. de Carcer, and M. Malumbres
A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy
Carcinogenesis, May 1, 2007; 28(5): 899 - 912.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Boyapati, M. Yan, L. F. Peterson, J. R. Biggs, M. M. Le Beau, and D.-E. Zhang
A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy
Blood, May 1, 2007; 109(9): 3963 - 3971.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Groth-Pedersen, M. S. Ostenfeld, M. Hoyer-Hansen, J. Nylandsted, and M. Jaattela
Vincristine Induces Dramatic Lysosomal Changes and Sensitizes Cancer Cells to Lysosome-Destabilizing Siramesine
Cancer Res., March 1, 2007; 67(5): 2217 - 2225.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. Trachana, K. H. M. van Wely, A. A. Guerrero, A. Futterer, and C. Martinez-A
Dido disruption leads to centrosome amplification and mitotic checkpoint defects compromising chromosome stability
PNAS, February 20, 2007; 104(8): 2691 - 2696.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Iwanaga, Y.-H. Chi, A. Miyazato, S. Sheleg, K. Haller, J.-M. Peloponese Jr., Y. Li, J. M. Ward, R. Benezra, and K.-T. Jeang
Heterozygous Deletion of Mitotic Arrest-Deficient Protein 1 (MAD1) Increases the Incidence of Tumors in Mice
Cancer Res., January 1, 2007; 67(1): 160 - 166.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Y. Yamada and G. J. Gorbsky
Spindle checkpoint function and cellular sensitivity to antimitotic drugs
Mol. Cancer Ther., December 1, 2006; 5(12): 2963 - 2969.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. M. Chin and R. Herbst
Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint.
Mol. Cancer Ther., October 1, 2006; 5(10): 2580 - 2591.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
N. Chester, H. Babbe, J. Pinkas, C. Manning, and P. Leder
Mutation of the Murine Bloom's Syndrome Gene Produces Global Genome Destabilization.
Mol. Cell. Biol., September 1, 2006; 26(17): 6713 - 6726.
[Abstract] [Full Text] [PDF]

Home page
 Sci Aging Knowl EnvironHome page
W. Dai and X. Wang
Aging in check.
Sci. Aging Knowl. Environ., March 15, 2006; 2006(7): pe9 - pe9.
[Abstract] [Full Text]

Home page
 JCBHome page
D. J. Baker, K. B. Jeganathan, L. Malureanu, C. Perez-Terzic, A. Terzic, and J. M.A. van Deursen
Early aging-associated phenotypes in Bub3/Rae1 haploinsufficient mice.
J. Cell Biol., February 13, 2006; 172(4): 529 - 540.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Yuan, Y. Xu, J.-H. Woo, Y. Wang, Y. K. Bae, D.-S. Yoon, R. P. Wersto, E. Tully, K. Wilsbach, and E. Gabrielson
Increased Expression of Mitotic Checkpoint Genes in Breast Cancer Cells with Chromosomal Instability
Clin. Cancer Res., January 15, 2006; 12(2): 405 - 410.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
M. Kim, K. Murphy, F. Liu, S. E. Parker, M. L. Dowling, W. Baff, and G. D. Kao
Caspase-Mediated Specific Cleavage of BubR1 Is a Determinant of Mitotic Progression
Mol. Cell. Biol., November 1, 2005; 25(21): 9232 - 9248.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
D. O. Cowley, G. W. Muse, and T. Van Dyke
A Dominant Interfering Bub1 Mutant Is Insufficient To Induce or Alter Thymic Tumorigenesis In Vivo, Even in a Sensitized Genetic Background
Mol. Cell. Biol., September 1, 2005; 25(17): 7796 - 7802.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
T. Oikawa, M. Okuda, Z. Ma, R. Goorha, H. Tsujimoto, H. Inokuma, and K. Fukasawa
Transcriptional Control of BubR1 by p53 and Suppression of Centrosome Amplification by BubR1
Mol. Cell. Biol., May 15, 2005; 25(10): 4046 - 4061.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. B. Smilenov, H. B. Lieberman, S. A. Mitchell, R. A. Baker, K. M. Hopkins, and E. J. Hall
Combined Haploinsufficiency for ATM and RAD9 as a Factor in Cell Transformation, Apoptosis, and DNA Lesion Repair Dynamics
Cancer Res., February 1, 2005; 65(3): 933 - 938.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
F. Sun, I. Betzendahl, F. Pacchierotti, R. Ranaldi, J. Smitz, R. Cortvrindt, and U. Eichenlaub-Ritter
Aneuploidy in mouse metaphase II oocytes exposed in vivo and in vitro in preantral follicle culture to nocodazole
Mutagenesis, January 1, 2005; 20(1): 65 - 75.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Wang, X. Hu, X. Ding, Z. Dou, Z. Yang, A. W. Shaw, M. Teng, D. W. Cleveland, M. L. Goldberg, L. Niu, et al.
Human Zwint-1 Specifies Localization of Zeste White 10 to Kinetochores and Is Essential for Mitotic Checkpoint Signaling
J. Biol. Chem., December 24, 2004; 279(52): 54590 - 54598.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Myung, S. Smith, and R. D. Kolodner
Mitotic checkpoint function in the formation of gross chromosomal rearrangements in Saccharomyces cerevisiae
PNAS, November 9, 2004; 101(45): 15980 - 15985.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. J. P. L. Kops, D. R. Foltz, and D. W. Cleveland
Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint
PNAS, June 8, 2004; 101(23): 8699 - 8704.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dai, W.
Right arrow Articles by Rao, C. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dai, W.
Right arrow Articles by Rao, C. V.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online